Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy (Record no. 95836)

000 -LEADER
fixed length control field 03998nam a22004935i 4500
001 - CONTROL NUMBER
control field 978-1-4614-7070-0
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20140220082827.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 130428s2013 xxu| s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781461470700
-- 978-1-4614-7070-0
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/978-1-4614-7070-0
Source of number or code doi
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC261-271
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED062000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 614.5999
Edition number 23
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Bonavida, Benjamin.
Relator term editor.
245 10 - TITLE STATEMENT
Title Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy
Medium [electronic resource] :
Remainder of title Targeted Therapies to Reverse Resistance /
Statement of responsibility, etc edited by Benjamin Bonavida.
264 #1 -
-- New York, NY :
-- Springer New York :
-- Imprint: Springer,
-- 2013.
300 ## - PHYSICAL DESCRIPTION
Extent XIII, 260 p. 30 illus., 23 illus. in color.
Other physical details online resource.
336 ## -
-- text
-- txt
-- rdacontent
337 ## -
-- computer
-- c
-- rdamedia
338 ## -
-- online resource
-- cr
-- rdacarrier
347 ## -
-- text file
-- PDF
-- rda
490 1# - SERIES STATEMENT
Series statement Resistance to Targeted Anti-Cancer Therapeutics,
International Standard Serial Number 2196-5501 ;
Volume number/sequential designation 1
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Preface -- Multidrug resistance in cancer: a tale of ABC drug transporters -- Multidrug resistance: a role for membrane physics, pH and drug transporters -- Mechanisms and potential therapies for acquired resistance to inhibitors targeting the Raf or MEK kinases in cancer -- Mechanisms of resistance to targeted B-Raf therapies -- Role of β1integrins in the complication and drug resistance against lung cancer: targeting β1integrins to eradicate lung cancer -- Aldo-keto reductases as new therapeutic targets for colon cancer chemoresistance -- Overcoming drug resistance through elevation of ROS in cancer -- Cancer stem cells in resistance to cytotoxic drugs: implications in chemotherapy -- Two birds with a stone: molecular cancer therapy targeting signal transduction and DNA repair pathways -- Collateral sensitivity in drug-resistant tumor cells -- Human cancer resistance to trail-apoptotic pathway-targeted therapies -- The dark side of apoptosis -- Index.
520 ## - SUMMARY, ETC.
Summary, etc Patients with various cancers are treated with conventional chemotherapeutic drugs and the majority responds well to such therapies. However, there is a subset of patients who does not respond initially and another subset who no longer responds to further treatments. Clearly, in those two subsets of patients, the cancer cells exhibit mechanisms of resistance. One of the main challenges facing us to date is to develop new therapies to treat patients with the resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance. Such mechanisms have revealed gene products that directly regulate resistance and are targets for therapy. Of interest, several FDA-approved drugs were able to overcome drug resistance and have been successfully used clinically. They have been used as monotherapy or synergized with other therapies for the treatment of resistant tumors. This volume constitutes a total of twelve selective reviews by pioneer scientists in the field of cancer drug resistance. Specific mechanisms in drug resistance are reviewed and novel approaches are being proposed for therapeutic interventions. This volume is of general interest to scientists, clinicians, health care providers, and students.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Oncology.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Drug interactions.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Cytology.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Biomedicine.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Cancer Research.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Apoptosis.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Cell Biology.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Drug Resistance.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9781461470694
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title Resistance to Targeted Anti-Cancer Therapeutics,
-- 2196-5501 ;
Volume number/sequential designation 1
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://dx.doi.org/10.1007/978-1-4614-7070-0
912 ## -
-- ZDB-2-SBL

No items available.

2017 | The Technical University of Kenya Library | +254(020) 2219929, 3341639, 3343672 | library@tukenya.ac.ke | Haile Selassie Avenue